Global Artificial Intelligence in Cancer Diagnostics Market 2025-2035

Description

List of Tables

Global Artificial Intelligence in Cancer Diagnostics Market Size, Share & Trends Analysis Report by Application (Screening & Diagnosis, Tumor Identification, and Surveillance), by Type (Breast Cancer, Prostate Cancer, Lung Cancer, Colorectal Cancer, and Others, and by End User (Hospitals, Diagnostic centers, Research Organization, Medical Institute, and Academics), Forecast Period (2025-2035)

Industry Outlook

Artificial intelligence in the cancer diagnostics market is anticipated to grow at a CAGR of 4.0% during the forecast period. The increasing use of technologically advanced solutions for detecting cancer, mainly at early stages, contributes to AI in cancer diagnostics industry growth. With the rising number of startups & collaborations and increasing venture capital funding, also the government has high initiatives in healthcare expenditures. Increasing initiatives undertaken by the government to increase the adoption of AI-assisted technologies for cancer diagnosis are expected to boost market expansion.

Segmental Outlook

The global artificial intelligence in cancer diagnostics market is segmented by application, type, and End-user. Based on the application, the market is sub-segmented into screening & diagnosis, tumor identification, and surveillance. Based on the type, the market is sub-segmented into breast cancer, prostate cancer, lung cancer, colorectal cancer, and others, including cervical cancer, blood cancer, and bone cancer. Further, based on end users, the market is sub-segmented into hospitals, diagnostic centers, research organizations, medical institutes, and academics. Among the end users, the diagnostic centers sub-segment is anticipated to hold a considerable share of the market owing to the increasing government initiatives and funding in the healthcare sector.

The Screening & Diagnosis Segment is Anticipated to Drive the Market

The screening & diagnosis segment is predicted to derive AI in the cancer diagnostic market. The detection of cancer at an early stage is very crucial for improving patient survival rates, and AI is enhancing the efficiency of diagnostic procedures through technological improvements. The analysis of critical medical data such as mammograms, CT scans, and MRIs has grown easier through advanced machine learning and deep learning algorithms, which allow early identification of cancerous cells. AI additionally decreases diagnostic errors and helps healthcare workers detect tumors at microscopic levels, determine cancer stages, and forecast patient reactions to immunotherapy. With rising cancer rates and a need for faster, more reliable diagnostics, AI-powered screening technologies are being widely embraced in hospitals and diagnostic centers, accelerating market growth.

Regional Outlook

The global artificial intelligence in cancer diagnostics market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Russia, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia & New Zealand, ASEAN Countries, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America).

The North American Region is Expected to Grow at a Significant CAGR in the Global Artificial Intelligence in Cancer Diagnostics Market

Among these, North America is anticipated to hold a prominent share of the market across the globe, owing to the rising number of cancer cases around the globe. According to Canadian Cancer Statistics, 43% of women and 45% of men in Canada will have cancer in their lifetime. Nevertheless, to combat this problem, the country is actively adopting AI across the healthcare industry. The major factors that help in market expansion are business strategies, including mergers & acquisitions, portfolio expansions, and collaborations by market players to promote AI implementation in the oncology field. In the US. The rising demand for more accurate diagnostics and early-stage detection is increasing. The AI-powered medical imaging systems produce scans that assist radiologists in identifying patterns & indicating treatments for patients affected with cancer. This also raises the demand for AI to assist healthcare professionals in reshaping the diagnosis & treatment of cancer. For instance, in May 2021, the US government launched AI.gov, a dedicated website for requesting suggestions on the regulation, development, and deployment of AI in the US. This platform was introduced during the presidency of Joe Biden.

Market Players Outlook

The major companies serving artificial intelligence in cancer diagnostics market include IBM Corp, Pfizer Inc., Microsoft Corp, Janssen Pharmaceuticals, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in July 2021, PathAI completed the acquisition of Poplar Healthcare PLLC, an independent anatomic pathology laboratory services provider. Through this acquisition, the company would be able to integrate testing services into its existing artificial intelligence-powered pathology platform. Poplar offers specialized testing services in a range of areas, from oncology to women's health to dermatology.

Recent Development

In October 2024, Ataraxis AI, a premier AI-driven precision medicine business, emerged from stealth with major venture funding from Giant Ventures and Obvious Ventures. This grant allowed Ataraxis to create breakthrough AI-powered diagnostic testing. The business introduced Ataraxis Breast, the most complex clinically validated test available, which is also the first AI-native prognostic and predictive test for breast cancer. This breakthrough improves early detection, risk assessment, and individualized treatment plans. Ataraxis AI uses AI to transform cancer diagnoses, improving accuracy and patient outcomes while promoting precision medicine in oncology.

The Report Covers:

Market value data analysis of 2025 and forecast to 2035.
Annualized market revenues ($ million) for each market segment.
Country-wise analysis of major geographical regions.
Key companies operating in the global AI in cancer diagnostics market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
Analysis of market-entry and market expansion strategies.
Competitive strategies by identifying 'who-stands-where' in the market.

Product Code: OMR2027621

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
Global AI in Cancer Diagnostics Market Sales Analysis - Application | Type | End-User ($ Million)
1.1. Research Methodology
Primary Research Approach
Secondary Research Approach

2. Market Overview and Insights

2.1. Scope of the Study
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Global AI in Cancer Diagnostics Market Trends
- 2.2.2. Market Recommendations
- 2.2.3. Conclusion

3. Market Determinants

3.1. Market Drivers
- 3.1.1. Drivers For Global AI in Cancer Diagnostics Market: Impact Analysis
3.2. Market Pain Points and Challenges
- 3.2.1. Restraints For Global AI in Cancer Diagnostics Market: Impact Analysis
3.3. Market Opportunities

4. Competitive Landscape

4.1. Competitive Dashboard - Global AI in Cancer Diagnostics Market Revenue by Manufacturers
4.2. Key Company Analysis
- 4.2.1. Overview
- 4.2.2. Product Portfolio
- 4.2.3. Financial Analysis (Subject to Data Availability)
- 4.2.4. SWOT Analysis
- 4.2.5. Business Strategy
4.3. Top Winning Strategies by Market Players
- 4.3.1. Merger and Acquisition
- 4.3.2. Product Launch
- 4.3.3. Partnership And Collaboration

5. Global AI in Cancer Diagnostics Market by Application ($ Million)

5.1. Screening & Diagnosis
5.2. Tumor Identification
5.3. Surveillance

6. Global AI in Cancer Diagnostics Market by Type ($ Million)

6.1. Breast Cancer
6.2. Prostate Cancer
6.3. Lung Cancer
6.4. Colorectal Cancer
6.5. Others (Cervical Cancer, Blood Cancer, Bone Cancer, and Other)

7. Global AI in Cancer Diagnostics Market by End-User ($ Million)

7.1. Hospitals
7.2. Diagnostic Centres
7.3. Research Organization
7.4. Medical Institute and Academics

8. Regional Analysis

8.1. North American AI in Cancer Diagnostics Market Sales Analysis -Application | Type | End-User | Country ($ Million)
- 8.1.1. United States
- 8.1.2. Canada
8.2. European AI in Cancer Diagnostics Market Sales Analysis -Application | Type | End-User | Country ($ Million)
- 8.2.1. UK
- 8.2.2. Germany
- 8.2.3. Italy
- 8.2.4. Spain
- 8.2.5. France
- 8.2.6. Russia
- 8.2.7. Rest of Europe
8.3. Asia-Pacific AI in Cancer Diagnostics Market Sales Analysis -Application | Type | End-User | Country ($ Million)
- 8.3.1. China
- 8.3.2. Japan
- 8.3.3. South Korea
- 8.3.4. India
- 8.3.5. Australia & New Zealand
- 8.3.6. ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- 8.3.7. Rest of Asia-Pacific
8.4. Rest of the World AI in Cancer Diagnostics Market Sales Analysis -Application | Type | End-User | Country ($ Million)
- 8.4.1. Latin America
- 8.4.2. Middle East and Africa

9. Company Profiles

9.1. Cancer Center.ai
9.2. CureMetrix, Inc.
9.3. DeepMind Technologies Ltd.
9.4. Flatiron Health
9.5. Freenome Holdings, Inc.
9.6. Ibex Medical Analytics Inc.
9.7. iCAD, Inc.
9.8. Kheiron Medical Technologies Ltd.
9.9. Median Technologies PLC.
9.10. Medical EarlySign
9.11. NVIDIA Corp
9.12. Paige AI Inc.
9.13. Path AI Inc. (Quest Diagnostics Inc.)
9.14. RaySearch Laboratories
9.15. Siemens Healthcare Co.
9.16. SkinVision Roche Holding AG
9.17. Sophia Genetics SA
9.18. Tempus AI, Inc.
9.19. Therapixel
9.20. Whiterabbit.ai, Inc.